Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Prostate Cancer

Free Subscription 08.07.2019 2 AJR Am J Roentgenol 4 Anticancer Res 1 BJU Int 1 BMC Cancer 2 Br J Radiol 2 Cancer 1 Clin Cancer Res 1 Clin Med Insights Oncol 1 Endocrinology 5 Eur Urol 2 Int J Cancer 2 Int J Radiat Oncol Biol Phys 1 Int J Urol 2 J Cell Physiol 3 J Clin Oncol 1 J Nucl Med 1 Magn Reson Imaging 1 N Engl J Med 1 Nat Rev Cancer 1 PLoS Med 1 Proc Natl Acad Sci U S A 1 Prog Urol 6 Prostate

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AJR Am J Roentgenol

1. BARRAL M, Lefevre A, Camparo P, Hoogenboom M, et al
   In-Bore Transrectal MRI-Guided Biopsy With Robotic Assistance in the Diagnosis of Prostate Cancer: An Analysis of 57 Patients.
   AJR Am J Roentgenol. 2019 Jul 3:1-9. doi: 10.2214/AJR.19.21145.
   PubMed     Text format     Abstract available
   
   
2. DIAZ DE LEON A, Leyendecker JR, Otero-Muinelo S, Grewal H, et al
   Reproducibility of Index Lesion Size and Mean Apparent Diffusion Coefficient Values Measured by Prostate Multiparametric MRI: Correlation With Whole-Mount Sectioning of Specimens.
   AJR Am J Roentgenol. 2018 Aug 30:1-6. doi: 10.2214/AJR.17.19172.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

3. CROWLEY E, Rowan NJ, Faller D, Friel AM, et al
   Natural and Synthetic Isothiocyanates Possess Anticancer Potential Against Liver and Prostate Cancer In Vitro.
   Anticancer Res. 2019;39:3469-3485.
   PubMed     Text format     Abstract available
   
   
4. MAEHANA S, Matsumoto Y, Kojima F, Kitasato H, et al
   Interleukin-24 Transduction Modulates Human Prostate Cancer Malignancy Mediated by Regulation of Anchorage Dependence.
   Anticancer Res. 2019;39:3719-3725.
   PubMed     Text format     Abstract available
   
   
5. CASTRO MJ, Careaga VP, Sacca PA, Faraoni MB, et al
   Lupane Triterpenoids and New Derivatives as Antiproliferative Agents Against Prostate Cancer Cells.
   Anticancer Res. 2019;39:3835-3845.
   PubMed     Text format     Abstract available
   
   
6. CHANG LW, Hung SC, Wang SS, Li JR, et al
   Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
   Anticancer Res. 2019;39:3901-3908.
   PubMed     Text format     Abstract available
   
   

   
   BJU Int

7. KALAPARA AA, Nzenza T, Pan HY, Ballok Z, et al
   Detection and localisation of primary prostate cancer using (68) Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens.
   BJU Int. 2019 Jul 1. doi: 10.1111/bju.14858.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

8. HUMMEL S, Kohlmann W, Kollmeyer TM, Jenkins R, et al
   The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database.
   BMC Cancer. 2019;19:190.
   PubMed     Text format     Abstract available
   
   

   
   Br J Radiol

9. KISHAN AU, Tyran M, Weng J, Upadhyaya S, et al
   Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial.
   Br J Radiol. 2019;92:20181001.
   PubMed     Text format     Abstract available
   
   
10. KIM SJ, Lee SW
    Diagnostic accuracy of (F)18 flucholine PET/CT for preoperative lymph node staging in newly diagnosed prostate cancer patients; a systematic review and meta-analysis.
    Br J Radiol. 2019 Jul 5:20190193. doi: 10.1259/bjr.20190193.
    PubMed     Text format     Abstract available
    
    

    
    Cancer

11. MAHAL AR, Butler S, Franco I, Muralidhar V, et al
    Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.
    Cancer. 2019 Jun 28. doi: 10.1002/cncr.32332.
    PubMed     Text format     Abstract available
    
    
12. FANG AM, Glaser ZA, Rais-Bahrami S
    Increasing the use of active surveillance for prostate cancer in younger men.
    Cancer. 2019 Jun 28. doi: 10.1002/cncr.32333.
    PubMed     Text format    
    
    

    
    Clin Cancer Res

13. KOTHARI V, Goodwin JF, Zhao SG, Drake JM, et al
    DNA-dependent protein kinase drives prostate cancer progression through transcriptional regulation of the Wnt signaling pathway.
    Clin Cancer Res. 2019 Jul 2. pii: 1078-0432.CCR-18-2387.
    PubMed     Text format     Abstract available
    
    

    
    Clin Med Insights Oncol

14. JAYASEKERA J, Onukwugha E, Cadham C, Tom S, et al
    Epidemiological Determinants of Advanced Prostate Cancer in Elderly Men in the United States.
    Clin Med Insights Oncol. 2019;13:1179554919855116.
    PubMed     Text format     Abstract available
    
    

    
    Endocrinology

15. SABHARWAL N, Sharifi N
    HSD3B1 Genotypes Conferring Adrenal Restrictive and Adrenal Permissive Phenotypes in Prostate Cancer and Beyond.
    Endocrinology. 2019 Jul 4. pii: 5527766. doi: 10.1210/en.2019-00366.
    PubMed     Text format     Abstract available
    
    

    
    Eur Urol

16. LIN X, Helfand BT, Xu J
    Re: Daniel A. Leongamornlert, Edward J. Saunders, Sarah Wakerell, et al., Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. Eur Urol. In press. https://doi.org/10.1016/j.eur
    Eur Urol. 2019 Jun 24. pii: S0302-2838(19)30492.
    PubMed     Text format    
    
    
17. HOLSCHER T, Lohaus F, Wirth M, Troost EGC, et al
    Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus Zophel, Steffen Lock, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol
    Eur Urol. 2019 Jun 27. pii: S0302-2838(19)30506.
    PubMed     Text format    
    
    
18. DIRIX PR, Mercier C, Dirix LY
    Re: Fabian Lohaus, Klaus Zophel, Steffen Lock, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51.
    Eur Urol. 2019 Jun 26. pii: S0302-2838(19)30507.
    PubMed     Text format    
    
    
19. WEI Y, Wu J, Gu W, Qin X, et al
    Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.
    Eur Urol. 2019 Jun 24. pii: S0302-2838(19)30453.
    PubMed     Text format     Abstract available
    
    
20. RANASINGHE WKB, Reichard CA, Chapin BF
    Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
    Eur Urol. 2019 Jun 24. pii: S0302-2838(19)30499.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

21. BECKER F, Joerg V, Hupe MC, Roth D, et al
    Increased Mediator complex subunit CDK19 expression associates with aggressive prostate cancer.
    Int J Cancer. 2019 Jul 4. doi: 10.1002/ijc.32551.
    PubMed     Text format     Abstract available
    
    
22. SAWADA Y, Kikugawa T, Iio H, Sakakibara I, et al
    GPRC5A facilitates cell proliferation through cell cycle regulation and correlates with bone metastasis in prostate cancer.
    Int J Cancer. 2019 Jul 5. doi: 10.1002/ijc.32554.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

23. OSMAN SO, Leijenaar RT, Cole AJ, Lyons CA, et al
    CT-based Radiomics for Risk Stratification in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jun 26. pii: S0360-3016(19)33392.
    PubMed     Text format     Abstract available
    
    
24. MURALIDHAR V, Zhang J, Wang Q, Mahal BA, et al
    Genomic validation of three-tiered clinical sub-classification of high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jul 1. pii: S0360-3016(19)33398.
    PubMed     Text format     Abstract available
    
    

    
    Int J Urol

25. SEKIGUCHI A, Tsumura H, Kawakami S, Satoh T, et al
    Relationship between the dose to the bulbomembranous urethra and stricture after high dose-rate brachytherapy for prostate cancer: Matched-pair analysis.
    Int J Urol. 2019 Jun 30. doi: 10.1111/iju.14045.
    PubMed     Text format    
    
    

    
    J Cell Physiol

26. CHENG G, Song Z, Liu Y, Xiao H, et al
    Long noncoding RNA SNHG12 indicates the prognosis of prostate cancer and accelerates tumorigenesis via sponging miR-133b.
    J Cell Physiol. 2019 Jul 2. doi: 10.1002/jcp.29039.
    PubMed     Text format     Abstract available
    
    
27. CAIRES-DOS-SANTOS L, da Silva SV, Smuczek B, de Siqueira AS, et al
    Laminin-derived peptide C16 regulates Tks expression and reactive oxygen species generation in human prostate cancer cells.
    J Cell Physiol. 2019 Jun 28. doi: 10.1002/jcp.28997.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

28. DIRIX L
    Predictive Significance of Androgen Receptor Splice Variant 7 in Patients With Metastatic Castration-Resistant Prostate Cancer: The PROPHECY Study.
    J Clin Oncol. 2019 Jul 2:JCO1900811. doi: 10.1200/JCO.19.00811.
    PubMed     Text format    
    
    
29. ARAGON-CHING JB
    Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?
    J Clin Oncol. 2019 Jul 1:JCO1900977. doi: 10.1200/JCO.19.00977.
    PubMed     Text format    
    
    
30. SHARP A, Porta N, Lambros MBK, Welti JC, et al
    Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer.
    J Clin Oncol. 2019 Jul 2:JCO1901104. doi: 10.1200/JCO.19.01104.
    PubMed     Text format    
    
    

    
    J Nucl Med

31. RAY BANERJEE S, Minn IL, Kumar V, Josefsson A, et al
    Preclinical evaluation of (203/212)Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer.
    J Nucl Med. 2019 Jun 28. pii: jnumed.119.229393. doi: 10.2967/jnumed.119.229393.
    PubMed     Text format     Abstract available
    
    

    
    Magn Reson Imaging

32. GIGANTI F, Allen C, Piper JW, Mirando D, et al
    Sequential prostate MRI reporting in men on active surveillance: initial experience of a dedicated PRECISE software program.
    Magn Reson Imaging. 2018 Oct 20. pii: S0730-725X(18)30335.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

33. KLOTZ L
    Apalutamide for Metastatic, Hormone-Responsive Prostate Cancer.
    N Engl J Med. 2019;381:84-86.
    PubMed     Text format    
    
    

    
    Nat Rev Cancer

34. SRIVASTAVA S, Koay EJ, Borowsky AD, De Marzo AM, et al
    Cancer overdiagnosis: a biological challenge and clinical dilemma.
    Nat Rev Cancer. 2019;19:349-358.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Med

35. GROSSET AA, Ouellet V, Caron C, Fragoso G, et al
    Validation of the prognostic value of NF-kappaB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.
    PLoS Med. 2019;16:e1002847.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

36. GUI B, Gui F, Takai T, Feng C, et al
    Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Proc Natl Acad Sci U S A. 2019 Jul 2. pii: 1908547116.
    PubMed     Text format     Abstract available
    
    

    
    Prog Urol

37. KLEINCLAUSS F, Frontczak A, Balssa L, Lebdai S, et al
    [Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review].
    Prog Urol. 2019 Jun 29. pii: S1166-7087(19)30113.
    PubMed     Text format     Abstract available
    
    

    
    Prostate

38. LOLLI C, De Lisi D, Conteduca V, Gurioli G, et al
    Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Prostate. 2019;79:1211-1220.
    PubMed     Text format     Abstract available
    
    
39. YANG T, An Z, Zhang C, Wang Z, et al
    hnRNPM, a potential mediator of YY1 in promoting the epithelial-mesenchymal transition of prostate cancer cells.
    Prostate. 2019;79:1199-1210.
    PubMed     Text format     Abstract available
    
    
40. BLOM S, Erickson A, Ostman A, Rannikko A, et al
    Fibroblast as a critical stromal cell type determining prognosis in prostate cancer.
    Prostate. 2019 Jul 3. doi: 10.1002/pros.23867.
    PubMed     Text format     Abstract available
    
    
41. VEREP S, Erdem S, Ozluk Y, Kilicaslan I, et al
    The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: How safe is it to depend on bioptic pathology?
    Prostate. 2019 Jul 3. doi: 10.1002/pros.23873.
    PubMed     Text format     Abstract available
    
    
42. NAM RK, Benatar T, Wallis CJD, Kobylecky E, et al
    MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL.
    Prostate. 2019 Jul 3. doi: 10.1002/pros.23871.
    PubMed     Text format     Abstract available
    
    
43. WANG D, Wan X, Zhang Y, Kong Z, et al
    A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway.
    Prostate. 2019 Jul 3. doi: 10.1002/pros.23840.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: